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Protocol
AbstrACt
Introduction As patient assessment of health-related 
quality of life (HRQOL) in cancer clinical trials has 
increased over the years, so has the need to attach 
meaningful interpretations to differences in HRQOL scores 
between groups and changes within groups. Determining 
what represents a minimally important difference 
(MID) in HRQOL scores is useful to clinicians, patients 
and researchers, and can be used as a benchmark for 
assessing the success of a healthcare intervention. 
Our objective is to provide an evidence-based protocol 
to determine MIDs for the European Organisation for 
Research and Treatment for Cancer Quality of life 
Questionnaire core 30 (EORTC QLQ-C30). We will mainly 
focus on MID estimation for group-level comparisons. 
Responder thresholds for individual-level change will also 
be estimated.
Methods and analysis Data will be derived from 
published phase II and III EORTC trials that used the 
QLQ-C30 instrument, covering several cancer sites. 
We will use individual patient data to estimate MIDs for 
different cancer sites separately. Focus is on anchor-based 
methods. Anchors will be selected per disease site from 
available data. A disease-oriented and methodological 
panel will provide independent guidance on anchor 
selection. We aim to construct multiple clinical anchors 
per QLQ-C30 scale and also to compare with several 
anchor-based methods. The effects of covariates, for 
example, gender, age, disease stage and so on, will also 
be investigated. We will examine how our estimated MIDs 
compare with previously published guidelines, hence 
further contributing to robust MID guidelines for the EORTC 
QLQ-C30.
Ethics and dissemination All patient data originate 
from completed clinical trials with mandatory written 
informed consent, approved by local ethical committees. 
Our findings will be presented at scientific conferences, 
disseminated via peer-reviewed publications and also 
compiled in a MID ‘blue book’ which will be made available 
online on the EORTC Quality of Life Group website as a free 
guideline document.
IntroduCtIon 
Patient assessment of health-related quality 
of life (HRQOL) in cancer clinical trials 
has increased over the years.1 Consequently, 
there is greater need to attach meaningful 
interpretations to aggregated HRQOL 
scores, whether differences in HRQOL scores 
between groups or within-patient changes 
in HRQOL over time. Determining what 
represents a minimally important difference 
(MID) in HRQOL scores is useful to clini-
cians, patients and researchers, and can be 
used as a benchmark for assessing the success 
of a healthcare intervention (eg, a new treat-
ment) or the design of future clinical trials 
(eg, determining sample sizes).
MID has been defined as: ‘the smallest 
difference in score in the outcome of 
interest that informed patients or informed 
proxies perceive as important, either bene-
ficial or harmful, and which would lead the 
patient or clinician to consider a change in 
strengths and limitations of this study
 ► Several anchor-based methods will be applied and 
compared.
 ► Multiple clinical anchors will be constructed per 
QLQ-C30 scale.
 ► A library of minimally important differences (MIDs) 
will be established on the European Organisation for 
Research and Treatment for Cancer QLQ-C30 across 
various patient populations, according to cancer site.
 ► This study will supplement previously published 
MID guidelines, hence establishing more robust MID 
guidelines.
 ► Anchor-based MIDs can only be estimated for 
QLQ-C30 scales for which a suitable anchor is 
available in our database.
group.bmj.com on January 22, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Musoro ZJ, et al. BMJ Open 2018;8:e019117. doi:10.1136/bmjopen-2017-019117
Open Access 
the management’ (Schünemann and Guyatt, p594).2 It 
is important to note that there is a wide-range of termi-
nology for ‘clinical meaningful change’ in the literature. 
Notable distinctions in terminology have been made 
when referring to either group-level difference/change 
or individual-level change. A valuable and comprehensive 
critique on this topic and relevant references is given by 
King.3 In this manuscript, we shall use the term ‘MID’ to 
refer to group-level thresholds and ‘responder threshold 
(RT)’ to refer to individual-level change. This project will 
mainly focus on MID estimation and will make distinc-
tions between (1) group-level difference: cross-sectional 
differences in HRQOL scores between clinically-defined 
groups at a given time point, (2) group-level change: 
change in HRQOL scores within a group over time and 
(3) individual-level change: within-patient change in 
HRQOL scores over time. MIDs that are based on (1) and 
(2) are useful for interpreting group-based trial results, 
while RTs for individual-level change can be useful in 
trials as thresholds to define ‘responders’, that is, patients 
who improved (or conversely patients who deteriorated) 
by a certain amount.
There are two broad methods for estimating MIDs/
RTs; the anchor-based and distribution-based methods. 
The anchor-based approach has received much atten-
tion in the literature.4–10 This approach expresses differ-
ences or change in HRQOL scores by linking particular 
HRQOL domains either to known variables, which have 
clinical relevance, or to patient-derived/physician-de-
rived ratings of change in the particular domain.2 4 10 11 In 
this approach, it is crucial to evaluate the appropriateness 
of anchors. The usefulness of the estimated threshold 
will depend on the anchor selected, how adjacent groups 
are defined within that anchor, and the strength of the 
relationship (conceptually and empirically) between 
the anchor and the target HRQOL domain.3 It is worth 
noting that the estimated thresholds will depend on a 
range of factors, including the instrument, patient popu-
lation, selected anchors and the methods used. Hence 
a global rule for MIDs/RTs applicable to all situations is 
highly unlikely.11 12 It is recommended that thresholds be 
estimated by applying several anchor-based methods and 
using several types of anchors, and then to triangulate on 
a single value or small range of values.11 Also, the liter-
ature does not clearly distinguish between the methods 
for estimating group-level versus individual-level thresh-
olds. This study will offer a great opportunity to compare 
with results across several anchor-based methods.
Distribution-based methods, on the other hand, rely 
solely on the statistical distribution of HRQOL scores 
(do not consider patients’/clinicians’ perspective),13 14 
and have been recommended to be used as supportive 
evidence to anchor-based estimates.11
In this project, we focus on the anchor-based approach, 
particularly in a setting where both the anchors and 
HRQOL scores are collected longitudinally. The data will 
be derived from published phases II and III European 
Organisation for Research and Treatment for Cancer 
(EORTC) trials which assessed HRQOL using the EORTC 
core HRQOL questionnaire, QLQ-C30. The aim of the 
project is to provide an evidence-based approach to deter-
mine MIDs for HRQOL scores of the EORTC QLQ-C30. 
Specifically, the appropriateness of particular clinical 
anchors in determining MIDs will be empirically evalu-
ated. In addition, a library of MIDs will be established on 
the EORTC QLQ-C30 across various patient populations, 
according to cancer site (melanoma, lung, brain, etc) as 
well as stage of disease.
Osoba et al4 provided recommendations for small 
(5–10 points), moderate (10–20 points) and large 
changes (>20) for interpreting HRQOL scores of the 
EORTC QLQ-C30. This was based on individual data 
from patients with breast and small-cell lung cancers and 
included four of the EORTC QLQ-C30 scales (physical, 
emotional, social and global health). A global patient 
rating of change was the anchor. Similar findings were 
reported by King8 based on comparing group differ-
ences, from multiple cancer sites, using published study 
results. More recent guidelines by Cocks et al15 16 using 
anchor-based methods highlighted that previous guide-
lines may be too simplistic in that they do not differ-
entiate between the QLQ-C30 scales as well as between 
direction of change (improvement vs deterioration). 
These evidence-based guidelines further recommended 
using the lower bound as a minimal relevant threshold, 
arguing that large effect sizes (ES) were not always realis-
tically achievable in all settings.
In contrast to Osoba et al,4 this project will use multiple 
clinical anchors using clinical variables tailored to the 
specific cancer disease sites that are available in our data-
base. The guidelines of King8 and Cocks et al15 16 were 
based on meta-analyses of published studies, pooling 
across cancer sites, whereas we will use individual patient 
data to estimate MIDs for different cancer sites separately. 
Therefore, this project presents an opportunity to add 
to previously published MID guidelines for the EORTC 
QLQ-C30 scales, for example,4 6–8 15 16 and compare these 
to estimated MIDs from our study.
MEthods And AnAlysIs
datasets and definition
Databases used for the analysis
The data will mainly be extracted from published phase II 
and III EORTC clinical trials. We will include only studies 
that collected HRQOL data at baseline and follow-up 
using the EORTC QLQ-C30 and supplementary EORTC 
questionnaire modules. Cancer types include melanoma, 
lung, colorectal, brain, head and neck, prostate, breast, 
testis, ovarian, pancreas and oesophageal cancer. Data 
from more recent EORTC studies, completed during 
this project, will also be included as well as data from 
non-EORTC clinical trials when available.
Data will be pooled within each cancer site separately 
using study time (defined as days since randomisation) 
as the common temporal scale per patient. MIDs will be 
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established per cancer site, with attention to robustness 
across the different subpopulations.
The EORTC QLQ-C30
The focus of the analysis is on the EORTC QLQ-C30, a 
self-administered questionnaire designed for use in cancer 
clinical trials. The EORTC QLQ-C30 comprises 30 items, 
24 of which are aggregated into nine multi-item scales, 
that is, five functioning scales (physical, role, cognitive, 
emotional and social), three symptom scales (fatigue, 
pain and nausea/vomiting) and one global health status 
scale. The remaining six single-item (dyspnoea, appetite 
loss, sleep disturbance, constipation, diarrhoea and the 
financial impact) scales assess symptoms. The financial 
impact scale will be omitted from the analysis because 
suitable anchors are unlikely to exist.
Scoring of the EORTC QLQ-C30 scales will follow the 
standard procedures (see EORTC QLQ-C30 Scoring 
Manual17). For consistency in signs of the change scores 
across the various EORTC QLQ-C30 scales, the symptom 
scores will be reversed to follow the functioning scales 
interpretation, that is, all scales will be scored such that 
0 represents the worst possible score and 100 the best 
possible score. All versions of the EORTC QLQ-C30 will 
be used.17
Anchor selection
We hope to identify at least one suitable clinical anchor 
for each EORTC QLQ-C30 scale from among potential 
clinical factors (eg, laboratory measures, physiological 
measures and clinician ratings) that are available in the 
databases. No patient ratings of change (eg, subjective 
significance questionnaires) are available in the database. 
HRQOL scores will only be considered as anchors if valid 
MIDs are known. Since the QLQ-C30 yields 15 scales 
measuring a wide range of symptoms and functioning, 
the suitability of an anchor must be considered relative 
to specific HRQOL domains. A suitable anchor for any 
particular QLQ-C30 scale should fulfil several criteria. 
Most notably the anchor should be relevant for the disease 
indication, should have clear medical interpretation and 
clinicians should be familiar with it. Also, there should 
be a conceptual and empirical relationship between the 
anchor and its patient-reported counterpart.11
Anchors will be selected per cancer site. This exercise 
will be guided by a panel of five to six clinical experts (per 
disease site) who are familiar with the specific trials, as 
well as with the structure of the EORTC QLQ-C30. These 
experts will primarily be recruited from the EORTC QOL 
group and from the panel of investigators involved in 
the included studies. The clinical experts will be briefed 
on the purpose of the project and the importance of 
Figure 1 A flow diagram summarising the data (eg, the cancer sites, QLQ-C30 scales and types of clinical variables that will 
be used for anchor construction), the clinical anchor construction step and the main statistical methods which will be applied 
in this project. AP, appetite loss; CF, cognitive functioning; CO, constipation; DI, diarrhea; DY, dyspnea; ECDF, empirical 
cumulative distribution function; EF, emotional functioning; ES, effect sizes; FA, fatigue; HRQOL, health-related quality of life; 
MID, minimally important difference; NV, nausea/vomiting; PA, pain; PF, Physical functioning; RF, role functioning; ROC, receiver 
operating characteristic; RT, responder threshold; SD, standard deviation; SEM, standard error of measurement; SF, social 
functioning; SL, sleep disturbance. 
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selecting anchors that are clinically related to the corre-
sponding HRQOL scales.
Clinical anchors will be preselected based on avail-
ability (ie, the total that can be successfully matched 
to existing QLQ-C30 assessments), strength of correla-
tion with the corresponding EORTC QLQ-C30 scale 
and finally clinical plausibility. A clinical anchor will be 
matched to an EORTC QLQ-C30 form if their respective 
assessment dates are within a predefined window. This 
time window will be determined on a per trial basis to 
ensure that the underlying true associations in the data 
are preserved. First, a candidate list of relevant clinical 
variables will be assembled based on the availability within 
each disease site. The acceptable compliance rate (ie, 
availability of complete information on both the anchor 
and the HRQOL scale) will depend on both relative 
and absolute available numbers. We aim for compliance 
rates ≥50% and an effective sample size of at least 200 
patients with repeated observations after pooling data for 
each cancer site separately. Thereafter, we will evaluate 
how well the anchors correlate with the corresponding 
QLQ-C30 scale at various time points of interest. Either 
a Spearman’s rank, polyserial or polychoric correlation 
will be used, depending on the distribution of the pair 
of variables. The correlation between their change scores 
will also be checked. Revicki et al11 suggested a correla-
tion of ≥|0.30| as a measure of an acceptable association. 
Where achievable, however, anchors with much stronger 
correlations will be prioritised as suggested by recent 
simulation studies.18 The list of retained anchors will be 
independently scrutinised for clinical relevance by the 
clinical experts, who will help to define clinically rele-
vant cut-off points in the anchor. Multiple anchors will 
be constructed for each QLQ-C30 scale where possible. 
If no suitable anchors can be identified for a given scale, 
no anchor-based MID will be estimated and reported for 
that scale.
Availability of anchors
When an anchor is only available for a subset of trials, 
only that subset will be used. A table will be constructed 
to summarise the availability of each anchor in the set 
of trials, and the QLQ-C30 scales to which each anchor 
is related (conceptually, clinically and empirically). For 
each anchor, we will present how important change 
will be defined (as prescribed by our panel of clinical 
experts), along with the estimated correlation with the 
corresponding QLQ-C30 scale.
Preliminary analyses
a. Descriptive tabulation of the distribution of anchors 
and the EORTC QLQ-C30 scales will be made by tri-
al, and pooled across trials. If insufficient variation 
is present or missing data are substantial in any an-
chor or scale, its inclusion in further analyses will be 
re-evaluated.
b. As a first step to establish the validity of an an-
chor, correlations between the anchors and their 
corresponding QLQ-C30 scales will be calculated us-
ing all matched anchor/HRQOL scale pairs, regard-
less of time point. Scatter plots of the correlations will 
be inspected to gain greater understanding of bivar-
iate distributions. The correlations will be calculated 
taking potential confounding factors into account 
(eg, treatment, gender, age, disease stage, country, 
trial, etc), to investigate the robustness of the asso-
ciations in the overall population. Anchor/HRQOL 
scale pairs that fail to correlate at least 0.30 in at least 
one subgroup will be excluded from further consid-
eration. Subgroups with associations <0.30 may be 
excluded from further analysis, after discussion with 
the clinical experts. Similarly, we will investigate the 
correlation between change scores of the anchor 
and HRQOL scale over time. Priority will be given 
to anchor/HRQOL scale pairs with correlations of 
at least 0.30 when MIDs for change scores are to be 
calculated.
c. The HRQOL score will be presented descriptive-
ly (eg, mean, median, range and SD) at every time 
point of interest, within various subgroups (eg, treat-
ment, gender, age group, disease stage, country, tri-
al, etc), as well as in the overall population.
handling of missing data
Missing HRQOL data
We will cross-check compliance with the protocol 
schedule and verify the reasons for missing data. A 
cross-tabulation of the clinical anchors with HRQOL 
compliance will be made. We will evaluate the proportion 
of missing HRQOL forms per category of the anchor and 
also check if subjects with missing HRQOL forms differ 
systematically from those with complete HRQOL data. If 
systematic differences are found, a panel of methodolog-
ical experts will be consulted to suggest appropriate sensi-
tivity analyses (eg, imputation techniques) to check the 
robustness of the estimated thresholds.
Missing clinical anchor data
Clinical anchors will be selected in such a way that missing 
data is minimised. For each EORTC QLQ-C30 scale, the 
subset of anchors with the least amount of missing data 
will be prioritised. Similar to the handling of missing 
HRQOL data, we will also explore the anchor data to 
identify patterns as well as reasons for missingness.
statistical analysis
Cross-sectional analysis of HRQOL scores
Cross-sectional differences (ie, at the same time point) 
of HRQOL scores will be calculated between distinct 
subgroups of patients, where the grouping has been 
done on the clinical anchor. The categorisation based 
on the clinical anchor is expected to yield groups that 
are distinct in health state, as this property is part of 
the clinical anchor building and evaluation process. For 
each HRQOL scale, the difference in mean HRQOL 
between each pair of adjacent group categories 
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will be calculated at specific time points of interest, 
for example, at baseline, at the end of treatment and at 
the end of follow-up. In addition, we will calculate ES 
for these groups by dividing the difference of the mean 
HRQOL score from both groups by the SD between 
patients in either group.8
Anchor-based method for change scores
The focus will be on examining both group-level and 
individual-level change over time. We will compute all 
possible pairwise time point differences in HRQOL 
scores and combine the data. This means that a subject 
can contribute multiple change scores that are calculated 
across different pairs of time points, and the resulting 
dependency within the data will be accounted for when-
ever a regression model is applied. We will consider 
specific time intervals, namely changes in HRQOL scales 
in the periods between start and end of treatment, and 
between end of treatment and end of follow-up as these 
are often well defined across several studies. Further-
more, depending on the study design and setting, we 
will consider additional shorter time intervals prior to 
the end of treatment where feasible. Subjects will be 
assigned to distinct subgroups reflecting various levels 
of change (eg, no change, small positive changes, large 
positive changes, small negative changes or large negative 
changes) based on the clinical anchor(s). These groups 
will be referred to as clinical change groups (CCG) and 
they are mutually exclusive. For each pair of time points 
and for a given anchor, a patient can thus belong to only 
one CCG category.
Change in HRQOL score between two time points 
is commonly expressed as a simple difference. We will 
explore other ways to express this change, for example, 
using relative differences that correct for the scores at 
baseline or another previous time point. Table 1 presents 
a list of alternative summary scores for expressing change 
in HRQOL scores that will be explored. For each CCG, 
the summary scores will be presented descriptively (eg, 
mean, median, range and SD). Differences in HRQOL 
summary scores between adjacent CCGs will be evaluated 
using primarily non-parametric techniques.
a. Mean change method: For a given HRQOL scale and 
its corresponding anchor, the MID for improvement 
is equal to the mean summary score of the ‘small 
positive change’ CCG and the MID for deterioration 
is equal to ‘small negative change’ CCG. The mean 
summary scores of the ‘small change’ CCGs and that 
of the ‘no change’ CCG will be compared. If the 
mean summary score for ‘no change’ CCG is similar 
to any of the two ‘small change’ CCGs, the estimated 
MID is doubtful.19
b. Linear regression: The estimate of the numerical 
change in HRQOL summary scores (see table 1) that 
is associated with the transition between adjacent 
CCG categories will be determined using a linear re-
gression. Separate models will be fitted for improv-
ing and deteriorating scores based on the anchor. 
The outcome variable is the summary score, and the 
covariate is a binary anchor variable; coded as ‘no 
change’=0 and ‘small positive change’=1 for model 
on improvement, and ‘no change’=0 and ‘small neg-
ative change’=1 for model on deterioration. The re-
sulting β’s (ie, slope parameters) correspond to the 
MIDs for improvement and deterioration respec-
tively. This approach can be extended to correct for 
other covariates that could possibly affect the MID 
estimates.20
Table 1 Description of various summary scores for expressing changes in HRQOL scores over time
Name Formula Description
AD Q2 − Q1 Simple difference in the HRQOL between two time points.
The mean of the AD values from all subjects corresponds to the Osoba’s 
MID (Osoba et al4).
pAD Q2c − Q1c Applying AD per subgroup c=1 to 4, where c is based on baseline QOL values 
grouped as; 0–25, 26–50, 51–75 and 76–100.
RD1 – ordered Q2−Q1
Q1
× 100 Per cent change from previous value.
RD2 – sum Q2−Q1
Q2+Q1
Per cent change compared with sum.
Convention: if Q2=Q1=0 then RD2=0.
RD3 – baseline Q2−Q1
QB
Per cent change compared to baseline value (Q B). 
Fixed value Q2 MID is dependent on the observed value. This will result in a fixed threshold, 
not dependent on change in HRQOL score from previous value.
Slope Q2−Q1
T2−T1
The absolute difference between two time points is weighted by the 
corresponding time period.
Q
x
, HRQOL outcome at time point Tx.
AD, absolute difference; HRQOL, health-related quality of life; MID, minimally important difference; pAD, piecewise absolute difference; RD, 
relative difference; RS, raw scores; QOL, quality of life.
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c. Receiver operating characteristic (ROC) curves:  For 
each summary score, the ROC analysis will be used 
to estimate RTs based on an anchor. Changes in dif-
ferent directions will be examined separately. For 
example, for defining improvement, we will create 
an ‘at least minimally important change’ group us-
ing all CCGs for improvements, that is, small posi-
tive and large positive CCGs, and a ‘no minimally 
important change’ group using no change CCG and 
any level of worsening (ie, small negative and large 
negative CCGs). Different approaches will be used to 
calculate threshold values, for example, by; (1) mini-
mising the gap between sensitivity and specificity, (2) 
minimising the sum of 1-sensitivity and 1-specificity 
and (3) minimising the sum of squares of 1-sensitiv-
ity and 1-specificity.21 The various estimates will be 
compared and triangulation considered in order 
to establish robust guidelines. The assurance with 
which an estimated threshold can be used will de-
pend on their corresponding sensitivity and specific-
ity values. It is commonly not recommended to apply 
thresholds to individual patients when sensitivity and 
specificity are less than 75%.22
d. Empirical cumulative distribution function: For each 
possible value of a given summary score (see table 1) 
expressing change in the EORTC QLQ-C30 domains 
over time, the percentage of patients achieving at 
least that amount of change will be plotted separately 
for each CCG, and also separately for improving and 
deteriorating scores. The benefit of this approach is 
that the separation between CCGs may be visually 
compared across all values of the summary scores, 
thus offering a range of possible RTs for clinical rele-
vance that can be considered simultaneously.23 24
The estimated thresholds across these methods will be 
compared, and the percentage of patients with improved 
or deteriorated HRQOL scores will be reported. Recom-
mendation for using estimated RTs for classifying indi-
vidual patients will be based on whether the probability of 
misclassification is low22 or whether the RT values exceed 
the measurement error level by comparing the thresholds 
to the minimum detectable change (MDC).3 13 22 25 The 
MDC= 1.96 ∗ √2 ∗ SEM  25 represents the smallest change 
that can be considered to be above the measurement 
error. Usually, if the MDC is greater than the RT then the 
measure is insufficiently precise to monitor individual 
patients. Furthermore, when setting RTs, especially on 
domains that are computed based on a single item, we 
will check that the RTs align with the underlying change 
levels of the scale scores.26
Distribution-based methods
We will examine the distribution-based approaches based 
on the SD (standard deviation) criteria, for example, 
0.2 SD, 0.3 SD, 0.5 SD and the SEM (standard error of 
measurement).13 The SDs and SEM will be calculated on 
the summary scores (see table 1) yielding MIDs corre-
sponding to the rules above. Since this approach requires 
that the data are normally distributed, those summary 
scores that violate this assumption (based on standard 
testing techniques) will not be considered.
ES14 will be calculated by dividing the summary scores 
in table 1 by the pooled SD of subjects at baseline (ie, 
before treatment). This will be done for any two adjacent 
time points, for example, depending on whether the level 
of compliance is acceptable. As a variation we will also 
calculate the ES between adjacent time points by using 
the SD of subjects at the previous time point27
VAlIdAtIon And sEnsItIVIty AnAlysIs
stability of the estimated MIds
Internal validation
Characteristics, such as age, gender, disease stage, country, 
etc, typically influence the absolute score outcomes of 
many HRQOL scales.28 The stability of the estimated 
MIDs will therefore be investigated by including these 
factors (one at a time) and an interaction term with the 
anchor in a regression model. We will include as many 
sociodemographic and clinically relevant covariates as are 
available from the study database and that can be evalu-
ated by the available sample size.
External validation
For each cancer site in order to perform external valida-
tion, we will examine external (ie, non-EORTC) studies 
having comparable data. This is subject to the availability 
of such data.
handling the boundaries (floor and ceiling) effects
We will check for the proportion of patients with 
boundary (extreme) scores. For those patients where the 
later time point was a boundary score, the change over 
time may be incorrectly estimated by simple subtraction. 
The change in clinical anchor for these patients at the 
boundaries will be used to estimate the magnitude of the 
problem. The proportion of patients with a change in 
clinical anchor that is not reflected in the HRQOL change 
due to the boundary constraints would be an indication 
of a limiting boundary problem. As a sensitivity check, 
we will investigate how much the MIDs are affected if we 
include or exclude these patients.
ConClusIon
In this project, we will determine MID for HRQOL scores 
of the EORTC QLQ-C30, using empirical individual 
patient data. The main focus is on the anchor-based 
approach. We aim to construct multiple anchors per 
QLQ-C30 multiple-item or single-item scale and apply 
and compare results from several anchor-based methods 
as recommended in the literature.11 19 Figure 1 presents 
a flow diagram summarising the key data component, 
the clinical anchor construction procedure and the main 
statistical methods which will be applied in this project. 
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Hopefully, the resulting MID estimates can triangulate to 
one value or a small range of values.
It is important to highlight that there are diverse opin-
ions in the literature on whether or not it is plausible to use 
the same methods for interpreting individual-level change 
versus group-level differences/change. For instance, the 
mean change method and the ROC curve method have 
been labelled to be appropriate for comparing group-level 
and individual-level change, respectively.20 29  On the other 
hand, both methods have been recommended to be useful 
for estimating MIDs that are useful for interpreting either 
group-level or individual-level change as long as the anchor 
is available at the individual level .22 30 31 We will compare 
and contrast MID estimates from the different methods to 
provide empirical evidence, and assess whether it is possible 
to apply a simplified guideline to between group differ-
ences/change and individual-level change.
A strength of our research is its integral combination of 
both clinical and methodological expertise. The findings 
will ultimately improve the interpretation of the QLQ-C30 
scale scores in clinical trials by providing empirical guide-
lines for relevant improvements and deteriorations.
Each year, there are over 5000 newly registered down-
loads of the EORTC quality-of-life measures. The infor-
mation from our research will be of added value to all 
its users (eg, pharma and academic) since a frequent 
issue raised by regulators and trial sponsors is an under-
standing of MID.
The main limitations of this project are that anchor-
based MIDs can only be estimated for QLQ-C30 scales 
for which a suitable anchor is available in the database. 
Also, the available anchors rely exclusively on clinical 
observations or interpretations. Unfortunately, patient 
ratings of change (eg, subjective significance question-
naires) are not available in the study database. We will 
consider using other HRQOL scores as a way to include 
the patient’s perspective if valid MIDs are known for the 
given HRQOL scores.
Overall, this project will supplement previously 
published research by using individual patient data to 
estimate MIDs for different cancer sites separately, hence, 
further providing evidence to robust and practical MID 
guidelines for the EORTC QLQ-C30.
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